[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"limbal-stem-cell-deficiency-lscd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:limbal-stem-cell-deficiency-lscd":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100645432","clinical-predictors-of-visual-outcome-in-patients-affected-with-ocular-surface-diseases-100645432",false,"NCT07694817","Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases","Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases: Single Center Retrospective-prospective Clinical Study","OSD","Inclusion Criteria:\n\n* The participant is willing and able to provide written informed consent for study participation (prospective cohort).\n* Adult participants aged ≥18 years at the time of inclusion.\n* Clinically confirmed diagnosis of OSD, including but not limited to inflammatory keratopathies, neurotrophic keratopathy, exposure keratopathy, limbal stem cell deficiency, post-surgical or post-traumatic corneal alterations.\n* Measurable BSCVA obtained through standardized manifest refraction and ETDRS chart testing at baseline.\n* Available dataset for the diagnostic tests required by the study (e.g., corneal topography, pachymetry, confocal microscopy, corneal sensitivity testing, slit-lamp imaging, tear cytokine analysis, impression cytology).\n* Willingness and ability to attend follow-up visits and complete all study-related procedures according to the study schedule.\n\nExclusion Criteria:\n\n* Change of retinal, optic nerve, or macular pathology that may affect best spectacle-corrected visual acuity independently of the cornea or ocular surface (e.g., age-related macular degeneration, diabetic macular edema, optic neuropathy) in the period of study\n* History of intraocular or corneal surgery within 3 months prior to baseline evaluation.\n* Active intraocular inflammation, glaucoma with uncontrolled intraocular pressure, or corneal conditions not compatible with accurate imaging or measurement (e.g., severe scarring, leukoma).\n* Uncontrolled systemic diseases that may impair vision or corneal health (e.g., advanced diabetes, autoimmune disease in active phase).\n* Inability or unwillingness to attend follow-up visits or complete study assessments.\n* Pregnant or breastfeeding women will not be enrolled, as hormonal fluctuations can alter tear film and ocular surface physiology","ALL",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","This retrospective-prospective study aims to identify the diagnostic parameters most predictive of BSCVA in patients with OSD. Clinical, structural, and biochemical data will be collected from standard-of-care examinations and patient-reported outcome questionnaires. The goal is to determine the most informative biomarkers for visual prognosis, streamline diagnostic workflows, and support individualized management of OSD.",[24,25,26,27,28,29],"Neurotrophic Keratopathy","Exposure Keratopathy","Limbal Stem Cell Deficiency (LSCD)","Cornea Abnormality","Cornea Disease","Cornea Inflamed","NOT_YET_RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-14","ACTUAL",{"date":36,"type":20},"2026-07",{"date":38,"type":20},"2029-12",{"name":40,"class":41},"IRCCS San Raffaele","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":58,"locationsCount":42},"100625419","brm421-ophthalmic-solution-in-patients-with-limbal-stem-cell-deficiency-100625419","NCT07422389","BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency","Intermediate-Size Patient Population Use of BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency","Inclusion Criteria:\n\n* Adult patients with mild to moderate LSCD who unsatisfied with the standard of care treatments and who seek the treatment with BRM421 Ophthalmic Solution. Patients scheduled for LSC transplant may be included, but treatment with BRM421 should begin only after the surgery.\n* Be able to sign the informed consent and follow with investigator instructions.\n* If a female is of childbearing potential, they must: use an acceptable means of birth control (acceptable methods of contraception include: hormonal oral, implantable, injectable, or transdermal contraceptives, mechanical spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner) and have a negative urine pregnancy test at the time of consent.\n\nExclusion Criteria:\n\n* The patients eligible for the BRIM clinical trial(s).\n* The patients diagnosed with primary LSCD which is the genetic mutations that lead to LSC dysfunction or destruction.\n* Have a condition or a situation in which the investigator feels the patients is not suitable and may put the patient at significant risk.\n* Be a female who is pregnant, nursing, or planning a pregnancy at the time of consent. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal oral, implantable, injectable, or transdermal contraceptives; mechanical spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. The risks of BRM421 among pregnant patients are not known.","18 Years","EXPANDED_ACCESS","The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops.\n\nParticipants will:\n\n* Use BRM421 two times a day for at least 12 weeks\n* Visit the clinic monthly for checkups and tests",[26],"AVAILABLE","2026-02-12",{"date":57,"type":34},"2026-02-20",{"name":59,"class":60},"BRIM Biotechnology Inc.","INDUSTRY"]